Protagonist Therapeutics, Inc. (PTGX)
NASDAQ: PTGX · Real-Time Price · USD
44.91
-1.25 (-2.72%)
At close: Apr 24, 2025, 4:00 PM
44.90
-0.01 (-0.01%)
After-hours: Apr 24, 2025, 7:53 PM EDT
Protagonist Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Protagonist Therapeutics stock have an average target of 66.5, with a low estimate of 51 and a high estimate of 80. The average target predicts an increase of 48.09% from the current stock price of 44.91.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Protagonist Therapeutics stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 3 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $80 | Strong Buy | Reiterates | $80 | +78.15% | Apr 10, 2025 |
| Wedbush | Wedbush | Buy Reiterates $70 | Buy | Reiterates | $70 | +55.88% | Mar 28, 2025 |
| Truist Securities | Truist Securities | Strong Buy Maintains $60 → $76 | Strong Buy | Maintains | $60 → $76 | +69.25% | Mar 11, 2025 |
| BMO Capital | BMO Capital | Buy Reiterates $62 → $72 | Buy | Reiterates | $62 → $72 | +60.34% | Mar 11, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $80 | Strong Buy | Maintains | $54 → $80 | +78.15% | Mar 11, 2025 |
Financial Forecast
Revenue This Year
100.78M
from 434.43M
Decreased by -76.80%
Revenue Next Year
107.97M
from 100.78M
Increased by 7.13%
EPS This Year
-1.80
from 4.23
EPS Next Year
-1.49
from -1.80
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 236.3M | 179.2M | 211.9M | ||
| Avg | 100.8M | 108.0M | 137.8M | ||
| Low | 15.7M | 19.6M | 40.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -45.6% | 77.9% | 96.2% | ||
| Avg | -76.8% | 7.1% | 27.6% | ||
| Low | -96.4% | -80.6% | -62.8% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.97 | -0.56 | -0.37 | ||
| Avg | -1.80 | -1.49 | -1.40 | ||
| Low | -2.37 | -2.55 | -2.30 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.